ALFA Finder
08:26 IST
NSE
Business Update
Biocon Business Update
Biocon signed a licence agreement with Janssen to commercialise biosimilar Yesintek in nine more markets, including Australia, Brazil and China. No deal value is disclosed.
Biocon Ltd
Biocon Ltd news stories on ALFA NewsRead the news →- Share price
- ₹368.05
- Market cap
- ₹59,981 Cr
- Revenue (annual)
- ₹16,927 Cr
- Net profit (annual)
- ₹385.6 Cr
- P/E (TTM)
- 132.7×Sector 43.8×
- Promoter holding
- 44.68%+0.00% QoQ
- FII holding
- 8.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Earnings Call 8Regulatory Approval 6Other Announcement 6Annual General Meeting 6Business Update 5Management Change 4Financial Results 4Capital Structure Change 4Results Update 3New Order Win 3Fund Raise 3Board Meeting Date 3Product Launch 2Merger & Restructuring 2Board Meeting Outcome 2Acquisition 2Price Movement Clarification 1Partnership 1Legal & Regulatory 1Employee Stock Options 1Dividend 1Annual Report 1
Time
5 announcements with these filters
08:26 IST
NSE
Business Update
Biocon Business Update
Biocon's Pertuzumab biosimilar received a positive CHMP opinion from the EMA, marking a milestone in its European regulatory path. Final European Commission approval is pending.
08:40 IST
NSE
Business Update
Biocon Business Update
Biocon's US subsidiary received U.S. FDA approval for the Yesintek® prefilled autoinjector. This supplemental approval enhances the company's immunology portfolio.
08:41 IST
BSE
Business Update
Biocon Business Update
Biocon announced the publication of Phase III clinical data supporting the effectiveness of its biosimilar Yesafili™. The data reinforces clinical equivalence ahead of its US launch.
08:27 IST
NSE
Business Update
Biocon Business Update
Biocon Limited announced that the U.S. FDA completed a Pre-License Inspection at its Bengaluru biosimilars site. The inspection concluded with five procedural observations. The company plans to submit a corrective action plan and does not expect any impact on data integrity or quality oversight.